ARA-290 (Cibinetide) – Comprehensive Research Overview (2026)
ARA-290, also known as Cibinetide, is a synthetic 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin (EPO). It was engineered to retain EPO’s anti-inflammatory, neuroprotective, and reparative properties while eliminating its erythropoietic (red blood cell-stimulating) effects. ARA-290 selectively activates the innate repair receptor (IRR), a heteromeric complex of EPOR and CD131, which is upregulated in damaged or inflamed tissues. It is primarily researched for neuropathic pain, small fiber neuropathy, diabetic complications, and tissue protection.
→ View ARA-290 (for laboratory research use only)
Chemical Structure and Properties
- Amino Acid Sequence: Pyroglutamate-Glu-Glu-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (pE-EELERALNSS)
- Molecular Weight: ≈1,257 Da
- Form: Lyophilized powder for subcutaneous injection
- Key Feature: Non-hematopoietic EPO-derived peptide with high selectivity for the innate repair receptor
Mechanism of Action
ARA-290 binds with high affinity to the innate repair receptor (IRR), triggering:
- Anti-inflammatory signaling (↓ NF-κB and pro-inflammatory cytokines)
- Anti-apoptotic effects and protection against cell death
- Promotion of nerve regeneration and tissue repair
- Reduction of oxidative stress and fibrosis
It does not significantly activate the classical EPOR homodimer responsible for erythropoiesis, avoiding increases in hematocrit or thrombosis risk.
Clinical Evidence and Research Findings
ARA-290 has completed multiple Phase 2 trials with promising results in sarcoidosis-associated small fiber neuropathy (significant improvement in neuropathic symptoms and corneal nerve fiber density) and diabetic painful neuropathy (improved symptoms, metabolic control, and nerve function). It holds FDA Orphan Drug and Fast Track designations for sarcoidosis-associated neuropathic pain. Phase 3 studies are still needed for broader approval.
→ Interested in researching ARA-290? View Product Options
Benefits (Research & Clinical Observations)
- Reduction in neuropathic pain and improved nerve function
- Promotion of small fiber nerve regeneration
- Anti-inflammatory and tissue-protective effects
- Potential benefits in metabolic and ocular complications of diabetes
- No erythropoietic side effects (no hematocrit increase)
Typical Dosing Protocols (Off-Label / Compounded)
- Clinical trial doses: 4 mg subcutaneous once daily (sarcoidosis neuropathy trials)
- Off-label protocols: 1–4 mg subcutaneous daily or every other day
- Cycles: 4–12 weeks; effects on nerve regeneration may persist after treatment
Safety Profile and Side Effects
ARA-290 has demonstrated a favorable safety profile in clinical trials.
Common side effects:
- Mild injection-site reactions
- Transient headache or fatigue (rare)
Advantages: No erythropoietic effects, no thrombosis risk associated with EPO. Contraindicated in known hypersensitivity.
ARA-290 vs LL-37 vs BPC-157 – Quick Comparison
| Aspect | ARA-290 | LL-37 | BPC-157 |
|---|---|---|---|
| Primary Focus | Neuroprotection & nerve repair | Antimicrobial & wound healing | Tissue repair & cytoprotection |
| Best For | Neuropathy, inflammation | Infections, wounds | Tendons, gut, injuries |
| Clinical Data | Phase 2 trials (positive) | Preclinical + early human | Extensive preclinical |
| FDA Status | Orphan Drug / Fast Track | Not approved | Not approved |
FAQ – Frequently Asked Questions
Is ARA-290 FDA approved? Not yet. It holds Orphan Drug and Fast Track designations and has completed Phase 2 trials. Phase 3 is pending.
Does ARA-290 increase red blood cell count like EPO? No. It is specifically engineered to avoid erythropoietic effects.
How long until results are seen? Neuropathic pain improvements have been reported within 4–8 weeks in clinical trials.
Can ARA-290 be combined with other peptides? Yes, though combination protocols should be supervised by a qualified clinician.
Summary
ARA-290 (Cibinetide) is a non-hematopoietic EPO-derived peptide with compelling Phase 2 clinical evidence for neuropathic pain and nerve regeneration. Its selective activation of the innate repair receptor offers a novel approach to tissue protection without erythropoietic risks. As with all compounds in this library, ARA-290 is not yet an approved drug and should only be considered under qualified medical supervision with appropriate monitoring.
For Laboratory Research Use View ARA-290 →
Disclaimer This overview is strictly educational and based on publicly available scientific literature and regulatory information as of April 2026. It does not constitute medical advice, endorsement, or encouragement of use. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.